1 Short report

- 2 Title: Efficacy of N-163 beta-glucan in beneficially improving biomarkers of relevance to
- 3 muscle function in patients with muscular dystrophies in a pilot clinical study.
- 4 **Running Title**: N-163 beta glucan improves muscle function in muscular dystrophies.

5 Authors:

- 6 Kadalraja Raghavan¹ (<u>drkraghavan@nichimail.jp</u>)
- 7 Thanasekar Sivakumar¹ (<u>siva.ctg@gmail.com</u>)
- 8 Koji Ichiyama² (<u>kcy@nichimail.jp</u>)
- 9 Naoki Yamamoto³ (<u>lb-20yamamoto@hospk.ncgm.go.jp</u>)
- 10 Mangaleswaran Balamurugan^{4,5} (<u>drmbalamurugan@gmail.com</u>)
- 11 Vidyasagar Devaprasad Dedeepiya⁶ (<u>drddp@nichimail.jp</u>)
- 12 Rajappa Senthilkumar^{2,7} (<u>rsk@nichimail.jp</u>)
- 13 Senthilkumar Preethy⁷ (<u>drspp@nichimail.jp</u>)
- 14 Samuel JK Abraham^{2,6,8-10} (<u>drsam@nichimail.jp</u>)
- 15 Affiliations:
- 16 1. Dept of Paediatric Neurology, Jesuit Antonyraj memorial Inter-disciplinary Centre for
- 17 Advanced Recovery and Education (JAICARE), Madurai, India
- Antony- Xavier Interdisciplinary Scholastics (AXIS), GN Corporation Co. Ltd., Kofu,
 Japan
- 20 3. National Centre for Global health and Medicine (NCGM), Chiba, Japan
- 4. Brain and Spine Hospital, Chennai, India

22	5. SIMS Hospital, Chennai, India
23	6. Mary-Yoshio Translational Hexagon (MYTH), Nichi-In Centre for Regenerative
24	Medicine (NCRM), Chennai, India.
25	7. Fujio-Eiji Academic Terrain (FEAT), Nichi-In Centre for Regenerative Medicine
26	(NCRM), Chennai, India.
27	8. Centre for Advancing Clinical Research (CACR), University of Yamanashi - School
28	of Medicine, Chuo, Japan.
29	9. R & D, Sophy Inc., Japan
30	10. Levy-Jurgen Transdisciplinary Exploratory (LJTE), Global Niche Corp, Wilmington,
31	DE, USA
32	
33	Corresponding author information:
34	Dr. Samuel JK Abraham,
35	II Department of Surgery & CACR,
36	University of Yamanashi, Faculty of Medicine
37	Address for correspondence: 3-8, Wakamatsu, Kofu, 400-0866, Yamanashi, Japan
38	Email id- drsam@nichimail.jp; Alternate email id: drspp@nichimail.jp
39	Fax: +81-55-235-7569
40	
41	Declarations:
42	Ethics approval and consent to participate
43	The study was registered in Clinical trials registry of India, CTRI/2022/05/042917

- 44 and approved by the ethics committee of Saravana Multispeciality Hospital-Institutional
- 45 Ethics Committee, India
- 46 *Consent for publication*
- 47 Not applicable

48 Availability of data and material

- 49 All data generated or analysed during this study are included in the article itself.
- 50 Funding
- 51 No external funding was received for the study

Competing

interests

Author Samuel Abraham is a shareholder in GN Corporation, Japan which holds shares of Sophy Inc., Japan., the manufacturers of novel beta glucans using different strains of Aureobasidium pullulans; a board member in both the companies and also an applicant to several patents of relevance to these beta glucans.

52 *Authors' contributions*

KR, NI and SA. contributed to conception and design of the study. KR, TS and RS helped in data collection and analysis. SA and SP drafted the manuscript. NY, KI, VD and MB performed critical revision of the manuscript. All authors read and approved the final manuscript.

57 Acknowledgements

58 The authors thank

59 1. The Government of Japan and the Prefectural Government of Yamanashi for a special
60 loan and M/s Yamanashi Chuo Bank for processing the transactions.

61	2. Ms. Sunitha, Mr. Vincent and the staff of JAICARE and Sarvee Integra, Dr.
62	Ragaroobine, Mr. Rajmohan from Nichi-In Centre for Regenerative Medicine (NCRM) for
63	their assistance during the clinical study and data collection of the manuscript.
64	3. Fr. Francis Xavier, Rector, Loyola College, Chennai, Fr. Vargheesh Antony and Fr.
65	Marianathan of JAICARE for their support during the clinical study.
66	4. Ms. Misa Takamoto, Mr. Masato Onaka, Mr. Yasushi Onaka of Sophy Inc, Kochi,
67	Japan for necessary technical support.
68	5. Ms. Yoshiko Amikura and staff of GN Corporation, Japan for their liaison assistance
69	with the conduct of the study.
70	6. Loyola-ICAM College of Engineering and Technology (LICET) for their support to
71	our research work.
72	
73	
74	
75	
76	
77	
78	
-0	
/9	
80	
81	

82 Abstract:

Background: Muscular dystrophies other than Duchenne muscular dystrophy (DMD) are genetic diseases characterized by increasing muscle weakness, loss of ambulation, and ultimately cardiac and respiratory failure. There are currently no effective therapeutics available. Having demonstrated the efficacy of a N-163 strain of Aureobasidium Pullulans (Neu-REFIX) produced B-1, 3- 1,6-Glucan in pre-clinical and clinical studies of Duchenne muscular dystrophy (DMD) earlier, we assessed the effectiveness of this novel Beta glucan in the other muscular dystrophies in the present study.

90 **Methods:** In this 60-day study, six patients with muscular dystrophies other than DMD 91 consumed one 8g gel of Neu-REFIX beta-glucan along with their usual standard of care 92 treatment regimen, and their biomarkers of relevance to muscle function such as serum 93 calcium (SC), creatinine phosphokinase (CPK), and alkaline phosphatase (ALP) levels along 94 with functional improvement criteria, viz., Medical research council (MRC) scale and North 95 Star Ambulatory assessment (NSAA) were assessed at baseline and following the 96 intervention.

97 Results: After the intervention, the SC levels significantly decreased from a mean baseline
98 value of 9.28 mg/dL to 8.31 mg/dL (p-value = 0.02). With a p-value of 0.29, the mean CPK
99 value dropped from 2192.33 IU/L to 1567.5 IU/L. Following the intervention, the ALP levels
100 dropped from 200.33 to 75.5 U/L (p-value =0.15). MRC scale improved in three out of six
101 patients. NSAA remained stable. There were no adverse effects.

102 Conclusion: This study has proven the safety of Neu REFIX beta-glucan food supplement 103 and its efficacy in improving both plasma biomarkers and functional parameters of muscle in 104 a short duration of 2 months. Further validation by evaluation of muscle function for a longer

- duration is recommended to confirm the efficacy of Neu-REFIX food supplement as a
- potential adjuvant DMT in muscular dystrophies.
- Keywords: Limb Girdle muscular dystrophy; N-163; beta glucan; disease modifying agent;
- Muscle function

125 Manuscript text:

126 Introduction:

127 Muscular dystrophies (MDs) are a group of about 30 distinct hereditary disorders with 128 specific anomalies such as variation in muscle fibre size, muscle fibre necrosis, scar tissue 129 formation, and inflammation. These MDs include dystrophinopathies such as Duchenne 130 muscular dystrophy (DMD), Emery-Dreifuss muscular dystrophies, congenital muscular 131 dystrophies, limb-girdle muscular dystrophies (LGMD), and fascioscapulohumeral muscular 132 dystrophy. The heterogeneity of these different disorders is delineated by a combination of 133 clinical, genetic, molecular, and pathological aspects [1]. Among MDs other than DMD, 134 Limb-girdle muscular dystrophy (LGMD) is common wherein LGMD1 refers to autosomal 135 dominant conditions and LGMD2 to recessive disorders. The sarcoglycan complex plays a 136 key role in the aetiology of LGMD with four types of autosomal recessive LGMD caused by 137 mutations in the sarcoglycan gene. LGMD affects the skeletal muscles, is genetically 138 inherited and causes progressive, primarily proximal muscular weakening due to muscle fibre 139 loss. To be defined as LGMD, the disease has to be present in at least two unrelated families, 140 the affected individuals have to be able to walk independently, the serum creatine kinase 141 (CK) level has to be elevated and the muscle imaging has to show degenerative changes, the 142 muscle histology has to show dystrophic changes, and the disease should eventually progress 143 to end-stage pathology for the most affected muscles [2]. Individual genetic mutations that 144 primarily cause protein shortage or misfolding give rise to the LGMD subtypes. Even though 145 it is unclear how these proteins affect mitochondrial function, it is obvious that they play a 146 part in energy production, maintaining Ca2+ homeostasis, or activating the apoptotic pathway 147 [3]. It is generally accepted that the prevalence of LGMD across all subtypes ranges from 0.8 148 to 6 per 100,000, For LGMD, both generic and disease-specific therapies are being 149 developed. There are now atleast 25 different therapeutic approaches in various phases of

development across all stages of research and commercialization. These treatments include anti-myostatin treatments, modulation of the immune system using steroids, Coenzyme Q10 and lisinopril, gene therapies such as Gamma-sarcoglycan gene-containing recombinant AAV1 vector-based therapy, SRP-9004: Sarcoglycan gene stimulator and small molecule therapies [4] but all have associated side effects and cannot be applied to all patients due to the heterogenous presentation of the disease.

156 We have previously reported the beneficial effects of a 1-3,1-6 beta-glucan from the N-163 157 strain of the black yeast Aureobasidium pullulans (Neu REFIX) in decreasing inflammatory 158 biomarkers such as interleukin (IL)-6, tumour growth factor (TGF)-, and IL-13 and increased 159 dystrophin levels as well as improved muscle strength in patients with DMD in a clinical 160 study conducted in 28 patients for a 45-day period [5] and then the muscle improvement in a 161 study of 6-months duration [6]. The gut microbiome was also found to be beneficially 162 reconstituted in the same study [7]. We also performed a pre-clinical study of this N-163 163 beta-glucan in a mdx mouse model[8], which showed a significant decrease in inflammation 164 score and fibrosis as well as levels of plasma alanine transaminase, aspartate 165 aminotransferase, lactate dehydrogenase, and haptoglobin; increased anti-inflammatory TGF-166 levels; and balanced regulation of the amount of centrally nucleated fibres indicative of 167 muscle regeneration [8] apart from increase in CD44 and MYH3 expression indicative of 168 muscle regeneration followed by maturation [9]. In the present study we have evaluated the 169 effects of this Neu REFIX B-glucan in patients with MDs other than DMD.

170 Materials and methods:

This trial was an investigator-initiated, single-centre, open-label, prospective, linear, singlearm clinical study of patients with MDs other than DMD. This study was conducted over a period of 60 days.

- 174 The intervention was consumption of one sachet of N-163 beta-glucan (Commercial name:
- 175 Neu-REFIX) once daily along with their standard of care treatment regimen.

176 Inclusion criteria:

- 177 1. Subjects diagnosed with LGMD and muscular dystrophies other than DMD
- 178 2. Male and Female subjects of age in between 3 years to 70 years
- 179 3. Subjects and legally authorized representative for vulnerable subjects must be willing to
- 180 participate in the study and provide a written informed consent
- 181 4. Subject willing to and able to comply with the protocol

182 Exclusion criteria:

- 183 1. Patients with a previous (within the past 1 month) or concomitant participation in any other
- 184 therapeutic trial
- 185 2. Subjects and legally authorized representative for vulnerable subjects who has not given
- 186 informed consent for this study
- 187 3. Subjects with history of multiple sclerosis
- 188 4. Subjects with history of any muscular atrophy
- 189 5. Pregnant and lactating females

190

191 Investigations:

Data on sex, date of birth, age, habits, medical history, medications, treatments, allergies (to foods and drugs), regular use of specific foods for health purposes, functional foods, health foods, consumption of foods high in beta-glucan and foods containing beta-glucan, and

195	consumption of immunity-boosting foods were collected as part of a background survey.			
196	Height, weight, body mass index, and temperature readings were recorded as well as a			
197	medical history. The following measurements and analysis were performed at baseline and at			
198	the end of the study (2 months).			
199	1. Levels of IL-6 and Myoglobin urea			
200	2. Levels of Creatinine Kinase, Titin, TNF-Alpha, Haptoglobin, Liver function test,			
201	Complete blood count, Cystatin C, ESR			
202	3. The Medical Research Council (MRC) Scale was used to measure muscle			
203	strength.			
204	4. North Star Ambulatory Assessment (NSAA)			
205	The participants were contacted every week for drug compliance and the recording of adverse			
206	effects, if any.			
207	Statistical analysis:			
208	Microsoft Office Excel statistics package and the software Origin 2021b were used for			
209	statistical analysis. Statistical significance was set at p<0.05.			
210	Results:			
211	Six patients, five male and one female were included in the study. The mean \pm standard			
212	deviation of age for the total study population was 28 ± 16.11 years (range, 8–51 years).			
213	Table 1 shows the genetic diagnosis of the subjects.			

- No adverse events were observed. No clinically significant changes from baseline data wereobserved on physical examination or in vital signs.
- 216 The serum calcium levels significantly decreased from a mean baseline value of 9.28 ± 0.59
- 217 mg/dL to 8.31 0.89 mg/dL post-intervention (p-value = 0.02). The mean CPK value

decreased from 2192.33 IU/L to 1567.5 IU/L (p-value =0.29). The ALP levels decreased from 200.33 to 75.5 U/L (p-value =0.15) post-intervention. The TNF-Alpha levels increased from a baseline of 17.95 ± 2.45 to 31.08 ± 25.81 pg/mL (p-value =0.12). There was not any significant changes in the other biochemical parameters measured. The MRC scale improved from 117.6 ± 22.59 to 120 ± 24.51 in three patients while the score decreased from $148.66 \pm$ 2.88 to 142.33 ± 0.57 in the remaining three patients. NSAA remained stable before and at the end of the study.

225

226 **Discussion:**

227 The goal of treatment approaches to muscular dystrophies (MD) including LGMD has been 228 to focus on improving the quality of life of patients while maintaining mobility and functional 229 independence for as long as possible apart from effectively managing the comorbidities. The 230 complexity of the disease makes the challenges enormous [10]. Any uniformity in strategy is 231 impossible due to high variation in presentation of the disease. The relative scarcity of 232 targeted therapeutics is explained by heterogenous patterns of inheritance, clinical 233 epidemiology, gene abnormalities, protein expression, and pathophysiology. It appears 234 extremely improbable that any one therapy strategy will be effective. Corticosteroids can alter the natural course of DMD by prolonging ambulation by two to three years and 235 236 supporting the maintenance of pulmonary function but in the case of other MDs such as 237 LGMD, majority of the treatment is supportive and interdisciplinary. Current objectives 238 typically focus on maintaining function rather than improving it [10].

Growth hormone, myoblast transfer, and myostatin inhibition have all failed to ameliorate MDs so far; available and reliable information on pharmacologic methods such as corticosteroids, myostatin inhibition, and myostatin inhibition is sparse. Gene therapies are

still under development and have not reached the clinic [10]. So, until a definitive approach is
identified, modulating the inflammation and immune response by a safe approach that can be
administered to all the patients in an easy manner is needed.

245 The biological response modifier glucan (BRMG) approach using the Neu REFIX Beta-246 Glucan has been by far safe and successful in ameliorating the inflammation, fibrosis in not 247 only DMD [5-9] but in multiple sclerosis (MS) [11], non-alcoholic steatohepatitis (NASH) 248 [12] and COVID-19 [13]. In DMD apart from beneficial outcome in biochemical parameters 249 and muscle function in studies of 45 days and 6 months duration, there has been increase in 250 levels of dystrophin which is the major protein that is affected by the gene mutation in DMD 251 and this outcome is usually expected only in gene or exon skipping therapies but not in 252 disease modifying treatments (DMTs) which makes the Neu REFIX Beta-glucan, an effective 253 DMT for muscular dystrophies.

254 Injury to the plasma membrane (PM) results in an abnormal calcium influx. Through the ER-255 resident calcium pumps and the calcium-activated ion channels, ER aids in the removal of 256 this increase in cytoplasmic calcium [14]. In order to facilitate calcium import into the ER, 257 ion channel maintains the electroneutrality of the ER lumen by anion import. When one or 258 both of these transporter activities are inhibited, cytosolic calcium excess and PM repair 259 (PMR) are both affected. Patients with MDs other than LGMD, due to disruption of the 260 calcium pumps and ion-channel mechanisms have compromised cytosolic and ER calcium 261 homeostasis. By Addressing calcium overload in these myofibers enables them to repair. In 262 the present study there has been significant decrease in serum calcium levels. Elevated levels 263 of enzymes such as CPK and ALP in MD patients is attributed to muscle damage and leakage 264 [15] .There has been significant decrease in CPK and ALT levels in the present report. 265 Though TNF-alpha is largely produced by macrophages as an inflammatory response 266 mediator and high circulating TNF- is thought to be a pathogenic component, it is now

known that TNF-Alpha is constitutively expressed by myoblasts and that its activity is momentarily elevated in developing myoblasts, therefore highlighting their physiological role in myogenesis and muscle regeneration [16]. In the current study, the increase in TNF-Alpha apart from improvement in MRC grading in 50% of the patients in a short duration of 60 days is worth being considered as a significant clinical improvement.

The smaller sample size, heterogeneity of the subjects, treatment regimens used, and a short duration are the study's limitations. However, the safety and effectiveness of this N-163produced beta-glucan dietary supplement in improving muscle function without causing side effects can be viewed as an essential adjunct to disease-modifying therapies for MDs.

276

277 **Conclusion:**

The N-163 Beta-Glucan (Neu-REFIX) is a promising disease-modifying pharmacological adjuvant in MDs other than DMD as it has improved the key biochemical parameters of relevance viz., serum calcium, CPK, ALT and TNF-Alpha apart from improving MRC in 50% of the patients in this short duration study of 60 days. Longer duration multi-centric studies are recommended to validate the potential of this safe, allergen-free, orally consumable food supplement as a DMT adjuvant in slowing the progression of MDs.

284

285

286

287

288 **References:**

- 1. Lovering RM, Porter NC, Bloch RJ. The muscular dystrophies: from genes to
- therapies. Phys Ther. 2005 Dec;85(12):1372-88.
- Lim LE, Campbell KP. The sarcoglycan complex in limb-girdle muscular dystrophy.
 Curr Opin Neurol. 1998 Oct;11(5):443-52.
- 3. Pozsgai E, Griffin D, Potter R, Sahenk Z, Lehman K, Rodino-Klapac LR, Mendell JR.
- 294 Unmet needs and evolving treatment for limb girdle muscular dystrophies.
- 295 Neurodegener Dis Manag. 2021 Oct;11(5):411-429. doi: 10.2217/nmt-2020-0066.
- 296 Epub 2021 Sep 2. PMID: 34472379.
- 4. Şahin İO, Özkul Y, Dündar M. Current and Future Therapeutic Strategies for Limb
- 298 Girdle Muscular Dystrophy Type R1: Clinical and Experimental Approaches.
- 299 Pathophysiology. 2021 May 18;28(2):238-249. doi:
- 300 10.3390/pathophysiology28020016. PMID: 35366260; PMCID: PMC8830477.
- 301 5. Raghavan K, Dedeepiya VD, Srinivasan S, Pushkala S, Subramanian S, Ikewaki N, 302 Iwasaki M, Senthilkumar R, Preethy S, Abraham S. Disease-modifying immune-303 modulatory effects of the N-163 strain of Aureobasidium pullulans-produced 1,3-1,6 304 Beta glucans in young boys with Duchenne muscular dystrophy: Results of an open-305 label, prospective, randomized, clinical comparative study.medRxiv 306 2021.12.13.21267706; doi: 10.1101/2021.12.13.21267706
- Kadalraja Raghavan, Thanasekar Sivakumar, Sudhakar S Bharatidasan, Subramaniam
 Srinivasan, Vidyasagar Devaprasad Dedeepiya, Nobunao Ikewaki, Rajappa
 Senthilkumar, Senthilkumar Preethy, Samuel JK Abraham. Efficacy of N-163 strain
 of Aureobasidium pullulans-produced beta-glucan in improving muscle strength and
 function in patients with Duchenne muscular dystrophy; Results of a 6-month nonrandomised open-label linear clinical trial. medRxiv 2023.04.29.23289260v1; doi:
- 313 10.1101/2023.04.29.23289260

7. Raghavan K, Dedeepiya VD, Yamamoto N, Ikewaki N, Iwasaki M, Dinassing A,
Senthilkumar R, Preethy S, Abraham SJK. Randomised trial of Aureobasidium
pullulans-produced beta 1,3-1,6-glucans in patients with Duchenne muscular
dystrophy: Favourable changes in gut microbiota and clinical outcomes indicating
their potential in epigenetic manipulation. medRxiv 2022.12.09.22283273; doi:
10.1101/2022.12.09.22283273

- Preethy S, Aoki Y, Minegishi K, Senthilkumar R, Abraham S. Resolution of fibrosis
 in mdx dystrophic mouse after oral consumption of N-163 strain of Aureobasidium
 pullulans produced biological response modifier β-glucan (BRMG). bioRxiv
 2022.11.17.516628; doi: 10.1101/2022.11.17.516628
- Abraham S, Sakamoto S, Higuchi T, Srinivasan S, Dedeepiya VD, Ikewaki N,
 Iwasaki M, Rajmohan M, Senthilkumar R, Preethy S. Enhanced muscle regeneration
 in MDX Duchenne muscular dystrophy-mice, proven by CD44 & MYH3, on
 consumption of A.Pullulans produced Neu REFIX β-Glucan. MDA Conference 2023,
 Dallas, Texas, USA.
- 329 10. Narayanaswami P, Weiss M, Selcen D, David W, Raynor E, Carter G, Wicklund M,
- Barohn RJ, Ensrud E, Griggs RC, Gronseth G, Amato AA; Guideline Development
- 331 Subcommittee of the American Academy of Neurology; Practice Issues Review Panel
- 332 of the American Association of Neuromuscular & Electrodiagnostic Medicine.
- Evidence-based guideline summary: diagnosis and treatment of limb-girdle and distal
- 334 dystrophies: report of the guideline development subcommittee of the American
- Academy of Neurology and the practice issues review panel of the American
- Association of Neuromuscular & Electrodiagnostic Medicine. Neurology. 2014 Oct
- 337 14;83(16):1453-63. doi: 10.1212/WNL.0000000000892. PMID: 25313375;
- 338 PMCID: PMC4206155.

339	11. Vidyasagar Devaprasad Dedeepiya, Chockanathan Vetrievel, Nobunao Ikewaki, Koji
340	Ichiyama, Naoki Yamamoto, Hiroto Kawashima, Sudhakar S Bharatidasan,
341	Subramaniam Srinivasan, Rajappa Senthilkumar, Senthilkumar Preethy, Samuel JK
342	Abraham. Improvement in Expanded Disability Status Scale (EDSS) and anti-
343	inflammatory parameters in patients with multiple sclerosis following oral
344	consumption of N-163 strain of Aureobasidium pullulans produced beta glucan in a
345	pilot clinical study.medRxiv 2023.05.14.23289953v2; doi:
346	10.1101/2023.05.14.23289953
347	12. Ikewaki N, Kurosawa G, Iwasaki M, Preethy S, Dedeepiya VD, Vaddi S,
348	Senthilkumar R, Levy GA, Abraham SJK. Hepatoprotective effects of Aureobasidium
349	pullulans derived Beta 1,3-1,6 biological response modifier glucans in a STAM-
350	animal model of non-alcoholic steatohepatitis. Journal of Clinical and Experimental
351	Hepatology-2022. https://doi.org/10.1016/j.jceh.2022.06.008
352	13. Raghavan K, Dedeepiya VD, Suryaprakash V, Rao KS, Ikewaki N, Sonoda T, Levy
353	GA, Iwasaki M, Senthilkumar R, Preethy S, Abraham SJK. Beneficial Effects of
354	novel aureobasidium pullulans strains produced beta-1,3-1,6 glucans on interleukin-6
355	and D-Dimer levels in COVID-19 patients; results of a randomized multiple-arm pilot
356	clinical study. Biomedicine and Pharmacotherapy
357	2021. sciencedirect.https://doi.org/10.1016/j.biopha.2021.112243.
358	14. Chandra G, Sreetama SC, Mázala DAG, Charton K, VanderMeulen JH, Richard I,
359	Jaiswal JK. Endoplasmic reticulum maintains ion homeostasis required for plasma
360	membrane repair. J Cell Biol. 2021 May 3;220(5):e202006035. doi:
361	10.1083/jcb.202006035. PMID: 33688936; PMCID: PMC7953257.

362	15. Zhu Y, Zhang H, Sun Y, Li Y, Deng L, Wen X, Wang H, Zhang C. Serum Enzyme
363	Profiles Differentiate Five Types of Muscular Dystrophy. Dis Markers.
364	2015;2015:543282. doi: 10.1155/2015/543282.
365	16. Chen SE, Jin B, Li YP. TNF-alpha regulates myogenesis and muscle regeneration by
366	activating p38 MAPK. Am J Physiol Cell Physiol. 2007 May;292(5):C1660-71. doi:
367	10.1152/ajpcell.00486.
368	
369	
370	
371	
372	
373	
374	
375	
376	
377	
378	
379	
380	
381	
382	

383 Table 1:

Subject	Gender	Age (Range) years	Genetic diagnosis
Ι	Female	11-15	LGMD Type 2E
II	Male	21-25	Miyoshi MD-1, LGMD Type 2B
III	Male	51-55	LGMD- Type 1
IV	Male	16-20	LGMD- Type 1
V	Male	41-45	Nonaka myopathy
VI	Male	6-10	Clinical diagnosis of MD; No genetic diagnosis

384

MD: Muscular Dystrophy; LGMD: Limb Girdle Muscular Dystrophy

385

386

387 Figures



Figure 1: Serum Calcium, Alkaline Phosphatase (ALP), Creatinine phosphokinase
 (CPK) and Tumour necrosis factor - Alpha in LGMD patients at baseline and 60 days
 post-intervention with N-163 B-Glucan (Neu REFIX)



Figure 2: Medical Research Council grading pre- and post-intervention of N-163 betaglucan in patients with LGMD showing increase in values (improvement) in I-III patients and decrease in IV-VI patients.

404			
405			
406			
407			
408			
409			
410			